More than 160 years after the Italian chemist Hugo Schiff first condensed an aldehyde with a primary amine, the family of compounds that bears his name is enjoying a remarkable renaissance. A new open-access review published in Discover Chemistry by M. Maruthavani and V. Gomathi of Seethalakshmi Ramaswami College in India surveys the recent literature on Schiff bases and their metal complexes, and the picture that emerges is striking: these azomethine-containing molecules, when paired with the right metal ion, can outperform established antibiotics and, in some cases, rival platinum-based chemotherapy drugs in laboratory assays. The review, compiled from studies indexed in Google Scholar, Web of Science and Scopus, positions Schiff base chelates as one of the most versatile platforms in modern medicinal inorganic chemistry.
The chemistry behind the excitement is elegantly simple. A Schiff base forms when the nitrogen lone pair of a primary amine attacks the electrophilic carbonyl carbon of an aldehyde or ketone, producing a fleeting carbinolamine intermediate that dehydrates to yield the characteristic azomethine group, R-CH=NR’. This imine nitrogen is the secret weapon: it donates electron density to almost any metal ion, anchoring the organic ligand to metals such as cobalt, nickel, copper, zinc, cadmium, vanadium, platinum and even rare earth elements. Depending on the ligand design, the resulting complexes can be mononuclear or polynuclear, homoleptic or heteroleptic, and can adopt geometries ranging from square planar and tetrahedral to octahedral and distorted pentagonal bipyramidal, as confirmed repeatedly by single-crystal X-ray diffraction.
Why does wrapping an organic molecule around a metal ion so often boost its biological punch? The review invokes two classical explanations. Overton’s concept suggests that chelation increases the lipophilicity of a compound, allowing it to slip more easily through the lipid membranes that guard bacterial and fungal cells. Tweedy’s chelation theory adds that coordination reduces the polarity of the metal ion by sharing its positive charge with the donor atoms, and may even delocalize electron density across the entire chelate ring. The result is a complex that penetrates cells more readily and then interferes with essential enzymatic processes. Electron-withdrawing and electron-donating substituents on the ligand fine-tune this electrophilicity and lipophilicity, which is why small structural changes can produce large swings in activity.
The antimicrobial evidence assembled in the review is extensive. In one representative study, cobalt, nickel, copper and zinc complexes of a Schiff base derived from 2-hydroxy-3-methoxy-5-nitrobenzaldehyde showed higher activity against Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa and Escherichia coli than the standard drugs ampicillin and chloramphenicol, and outperformed nystatin and griseofulvin against Candida albicans and other fungi. Elsewhere, a vanadium(IV) complex of a xipamide-salicylaldimine ligand beat both the free ligand and the parent drug griseofulvin against Aspergillus niger and Aspergillus flavus, while a copper complex built from a benzo[d][1,3]dioxole scaffold topped the screen against S. aureus and Klebsiella species.
Metal identity matters enormously, and the review documents clear activity trends across entire series. For complexes of a cuminaldehyde-L-histidine Schiff base, the antimicrobial ranking ran ligand < Zn(II) < Co(II) < Ni(II) < Cu(II), with the copper complex the strongest against E. coli, S. aureus and Aspergillus flavus. A similar hierarchy, Cu(II) > Co(II) > Ni(II) > Zn(II) > free ligand, appeared for tetradentate complexes derived from 2′,4′-dihydroxyacetophenone and ethylenediamine. Yet the pattern is not universal: cadmium and mercury complexes of furan-based Schiff bases showed remarkable activity, a zinc complex of a triazole-thiol ligand outshone its rivals against nine foodborne pathogens, and in one quinoline-derived series the free ligand actually beat most of its metal complexes. Geometry plays a role too, with a distorted tetrahedral Cu(II) sulfonamide complex outperforming its square planar Pd(II) analogue.
On the anticancer front, the review catalogues dozens of in vitro screens against cell lines spanning breast (MCF-7, MDA-MB-231), cervical (HeLa), colon (HT29, HCT116), liver (HepG2), lung (A549, H1299) and prostate (PC-3) cancers, most commonly using the MTT viability assay. Some results are eye-catching. A platinum(II) complex of naphthalene-derived hydrazinecarbothioamides exceeded the activity of cisplatin itself against MCF-7 breast cancer cells. A copper complex of a sulfamethoxazole Schiff base outperformed both cisplatin and carboplatin in the MDA-MB-231 breast cancer line. A cadmium complex achieved an IC50 of just 9 micrograms per millilitre against MCF-7 cells, and a zinc thiazole complex posted IC50 values between 5.3 and 6.2 micrograms per millilitre across four cell lines, though still short of doxorubicin.
Not every result is a triumph, and the review is candid about the failures. Copper complexes of dichloro-salicylidene sulfonamides fell short of cisplatin against MDA-MB-231 cells. Cobalt, nickel and copper chromone-thiadiazole complexes showed antitumor activity against HepG2 cells with IC50 values of roughly 18 to 20 micrograms per millilitre, well behind doxorubicin’s 4.73. In a series of dithiocarbazate zinc complexes, every ligand and complex was less active than the fluorouracil standard. These negative results matter: they map the boundaries of the field and underscore that metal choice, ligand substitution and cellular context jointly determine whether a chelate becomes a drug candidate or a dead end.
Beyond the petri dish, Schiff base metal complexes are proving useful across a surprising breadth of applications. Cobalt, iron and ruthenium complexes of hydroxybenzaldehyde-derived ligands catalyze the oxidation of cyclohexane to cyclohexanol; tridentate organocobalt complexes initiate emulsion polymerizations; and isothiosemicarbazone complexes exhibit nonlinear optical properties. Amino acid Schiff base complexes serve as radiotracers in nuclear medicine, macrocyclic dithiocarbazate complexes model oxygen transport in respiratory systems, and a benzofuran derivative related to these ligands acts as an antioxidant. The review also notes roles in sensors, pigments and dyes, polymer stabilization and analytical chemistry, reflecting the same coordination versatility that underpins the biological activity.
The authors conclude that the azomethine group is the common thread binding this vast literature together, and that metal complexation consistently enhances biological efficiency relative to the free ligands. For a field racing to find new antibiotics as resistance spreads and new cytotoxins as tumors evolve, Schiff base chelates offer a modular, synthetically accessible scaffold where chemists can dial in metal, geometry and substituents almost at will. The challenge now, the review implies, is translating these laboratory successes into compounds that survive the far harsher tests of pharmacokinetics, toxicity and clinical efficacy. But with copper complexes beating cisplatin in cell culture and simple chelates outperforming ampicillin, the 1864 discovery of Hugo Schiff may yet prove to be one of chemistry’s most enduring gifts to medicine.
Subject of Research: Antimicrobial and anticancer applications of Schiff base metal chelates
Article Title: A review on antimicrobial and anticancer applications of Schiff base chelates
Article References: Maruthavani, M., & Gomathi, V. (2026). A review on antimicrobial and anticancer applications of Schiff base chelates. Discover Chemistry, 3(1), Article 453. https://doi.org/10.1007/s44371-026-00845-9
Image Credits: AI Generated
DOI: 10.1007/s44371-026-00845-9
Keywords: Schiff base, metal complexes, coordination chemistry, antimicrobial activity, anticancer activity, azomethine, chelation theory, IC50, medicinal inorganic chemistry, MTT assay, bioinorganic chemistry, drug resistance
News Source: Bethany Barker. (October 13, 2026). Metal Meets Molecule: How Schiff Base Chelates Are Emerging as Antimicrobial and Anticancer Powerhouses. Scienmag.
